Abstract:Alzheimer's disease (AD) is the most common progressive central nervous system neurodegenerative disease globally (1) . At present, the treatment of AD involves only symptomatic medications which have continually demonstrated little efficacy (2) . Hericium erinaceus (HE), commonly known as lion's mane mushroom, has not yet been fully utilised among western pharmacology for its medicinal purposes, demonstrating a possible omittance of a highly beneficial neuro-altering substance. To date, studies that have investigated the potential medicinal properties of HE have found that various neuroprotective effects are exerted when following consumption (3) . The aim of this review is to systematically investigate the neuroprotective pathways impacted by dietary supplementation of HE, determine specific bio-compounds responsible, and highlight the importance of continued research to determine the true potential relevance of this therapeutic treatment for AD. Electronic databases were systematically searched for studies investigating the relationship between HE and AD. For inclusion in this review, human studies must have been of a clinical design involving adults >30 years that are healthy, have mild cognitive impairment, probably AD or memory deficits. Animal studies were required to involve interventions that directly impact AD-related mechanisms. The exclusion criteria involved any observational studies that involved participants with other neurological implications, or any studies that noted existing interventions (i.e., medications, post-surgery, dietary intervention). A study quality assessment was conducted for all qualified studies using Cochrane RoB2 tools. Data extraction was undertaken according to PRISMA guidelines. A total of 16 studies (including 3 human clinical trials and 13 animal model studies) met the criteria for inclusion. All studies included either behavioural, biochemical, ophthalmic, and neuroimaging assessments which demonstrated to be directly influenced by HE intake and highlighted key mechanisms previously associated with neurohealth promotion or neuropathological decline. Behavioural and biochemical clinical trial results revealed statistical differences (p < 0.05) between result comparison between HE and control groups and various week intervals. Animal model behavioural and biochemical assessments demonstrated positive findings. Histological assessments of AD-induced rodents following HE administration revealed statistically significant results (p < 0.05) in cholinergic transmitter and NGF concentrations, β-amyloid peptide plaque accumulation, and microglia and astrocyte activation compared to control groups. Evidence suggests that an intake of HE, specifically the compound erinacine-A may be an appropriate and relevant candidate for the future therapeutic treatment for the prevention and delayed progression of AD. Application of HE demonstrated numerous improvements in AD-related behaviour, biomarker parameters, histological features, and physiological mechanisms while neuroprotective and neurotrophic properties were also clearly established. Nevertheless, the review highlights the necessity for continued research specifically human clinical trials to contribute continued evidence surrounding the use of HE for AD, to provide direction for future research and provide constructive methods for the possible future targeting of AD populations.

Key Mechanisms and Potential Implications of Hericium erinaceus in NLRP3 Inflammasome Activation by Reactive Oxygen Species during Alzheimer’s Disease

Ganoderma Lucidum Triterpenoids (glts) Reduce Neuronal Apoptosis Via Inhibition of ROCK Signal Pathway in APP/PS1 Transgenic Alzheimer's Disease Mice

Hericium erinaceus: A possible future therapeutic treatment for the prevention and delayed progression of Alzheimer's disease? – A Systematic Review

The Neuroprotective Properties of Hericium erinaceus in Glutamate-Damaged Differentiated PC12 Cells and an Alzheimer’s Disease Mouse Model

Cognitive Healthy Aging in Mice: Boosting Memory by an Ergothioneine-Rich Hericium erinaceus Primordium Extract

Neuroinflammation and neurohormesis in the pathogenesis of Alzheimer's disease and Alzheimer-linked pathologies: modulation by nutritional mushrooms

Hericium erinaceus Improves Recognition Memory and Induces Hippocampal and Cerebellar Neurogenesis in Frail Mice during Aging

Eriodictyol and Homoeriodictyol Improve Memory Impairment in Aβ25–35-Induced Mice by Inhibiting the NLRP3 Inflammasome

Neuroprotective Metabolites of Hericium erinaceus Promote Neuro-Healthy Aging

Erinacine A-Enriched Hericium erinaceus Mycelium Delays Progression of Age-Related Cognitive Decline in Senescence Accelerated Mouse Prone 8 (SAMP8) Mice

Lion’s Mane Mushroom, Hericium erinaceus (Bull.: Fr.) Pers. Suppresses H2O2-Induced Oxidative Damage and LPS-Induced Inflammation in HT22 Hippocampal Neurons and BV2 Microglia

Structural characterization of polysaccharide purified from Hericium erinaceus fermented mycelium and its pharmacological basis for application in Alzheimer's disease: Oxidative stress related calcium homeostasis

Structural characterization of Hericium coralloides polysaccharide and its neuroprotective function in Alzheimer's disease

Structural characterization of polysaccharide purified from<i> Hericium</i><i> erinaceus</i> fermented mycelium and its pharmacological basis for application in Alzheimer's disease: Oxidative stress related calcium homeostasis

Neuroprotective effects of Hericium erinaceus (Bull.: Fr.) Pers. against high-dose corticosterone-induced oxidative stress in PC-12 cells

Mechanisms of NLRP3 Inflammasome Activation: Its Role in the Treatment of Alzheimer’s Disease

Calcium Modulation, Anti-Oxidant and Anti-Inflammatory Effect of Skin Allergens Targeting the Nrf2 Signaling Pathway in Alzheimer's Disease Cellular Models

Structural Characterization of Polysaccharide Purified from Amanita Caesarea and Its Pharmacological Basis for Application in Alzheimer's Disease: Endoplasmic Reticulum Stress

Network pharmacology analysis and experimental validation of Anemarrhenae Rhizoma in treating Alzheimer ' s disease

Erinacine A Prevents Lipopolysaccharide-Mediated Glial Cell Activation to Protect Dopaminergic Neurons against Inflammatory Factor-Induced Cell Death In Vitro and In Vivo

The Cerebral Protective Effect of Novel Erinacines from Hericium erinaceus Mycelium on In Vivo Mild Traumatic Brain Injury Animal Model and Primary Mixed Glial Cells via Nrf2-Dependent Pathways